Sign Up Today and Learn More About Imbria Pharmaceuticals Stock
Invest in or calculate the value of your shares in Imbria Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Imbria Pharmaceuticals Stock
Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.
About Imbria Pharmaceuticals Stock
Founded
2018
Headquarters
Boston, MA, US
Industries
Science and Engineering, Health Care, Biotechnology
Imbria Pharmaceuticals Press Mentions
Stay in the know about the latest news on Imbria Pharmaceuticals
Imbria Pharmaceuticals: $57.5 Million (Series B) Raised To Develop Novel Therapies For Cardiometabolic Diseases
pulse2 • Apr 15, 2025
Imbria Pharmaceuticals Raises $57.5M in Series B Financing
finsmes • Apr 12, 2025
Imbria secures $58 million to advance mid-stage trial for lead heart drug
thepharmaletter • Apr 12, 2025
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO
vcaonline • Apr 10, 2025
Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics
endpts • Apr 10, 2025
Imbria Pharmaceuticals Management
Leadership team at Imbria Pharmaceuticals
Board Member
Andrew Levin
Board Member
Charles Dunn
Join now and verify your accreditation status to gain access to:
- Imbria Pharmaceuticals Current Valuation
- Imbria Pharmaceuticals Stock Price
- Imbria Pharmaceuticals Management
- Available deals in Imbria Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Imbria Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Imbria Pharmaceuticals Revenue and Financials
- Imbria Pharmaceuticals Highlights
- Imbria Pharmaceuticals Business Model
- Imbria Pharmaceuticals Risk Factors
- Imbria Pharmaceuticals Research Report from SACRA Research
Trading Imbria Pharmaceuticals Stock
How to invest in Imbria Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Imbria Pharmaceuticals through EquityZen funds. These investments are made available by existing Imbria Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Imbria Pharmaceuticals stock?
Shareholders can sell their Imbria Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."